首页 / 院系成果 / 成果详情页

Prognostic value of primary tumor surgery in de novo stage IV breast cancer patients with different metastatic burdens: a propensity score-matched and population-based study 期刊论文

编号：

1746037f-4d31-420c-994a-defafc2bf256
作者：

Yang, YunSong#^[1,2]Chen, YingLe#^[3,4,5]Di, GenHong(狄根红)^[1,2]Jiang, YiZhou(江一舟)*^[1,2]Shao, ZhiMing*^[1,2,6]
语种：

英文
期刊：

TRANSLATIONAL CANCER RESEARCH ISSN：2218-676X 2019 年 8 卷 2 期 (614 - +) ; APR
收录：
关键词：

De novo stage IV breast cancer surgery propensity score matching (PSM) inverse probability of treatment weighting (IPTW) survival the Surveillance Epidemiology and End Results database (SEER)
摘要：

Background: Whether primary tumor surgery should be performed in breast cancer patients with metastatic disease at diagnosis has been debated for decades. This study aims to evaluate the value of primary tumor surgery with respect to the mortality of patients with de novo stage IV breast cancer and to define the heterogeneity of this population.
Methods: De novo stage IV patients from the Surveillance, Epidemiology and End Results database (SEER) from 2010 to 2015 were included in our study. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were used to achieve balanced baseline characteristics. The effect of surgery was assessed by Kaplan-Meier curves and Cox regression models.
Results: Of the 11,684 patients eligible for analysis, 3,730 (31.92%) received primary tumor surgery. Multivariate Cox regression in the PSM cohort revealed that surgery was associated with better outcomes than those in the nonsurgery group in terms of overall survival (OS) [hazard ratio (HR): 0.51; 95% Cl: 0.48-0.55; P<0.001] and breast cancer-specific survival (BCSS) (HR: 0.51; 95% CI: 0.47-0.55; P<0.001). IPTW analysis yielded similar results. In a subgroup analysis, surgery was associated with better survival in all subtypes with low metastatic burdens (<= 2 metastatic sites), but triple-negative breast cancer with a high metastatic burden (>2 metastatic sites) did not benefit from surgery (HR: 0.78; 95% Cl: 0.31-1.97, P=0.596 and 0.78, 95% CI: 0.31-1.97, P=0.596 for OS and BCSS, respectively).
Conclusions: Primary tumor surgery significantly prolonged the survival of patients with de novo stage IV breast cancer. However, triple-negative breast cancer patients with more than two metastatic sites may not benefit from surgery.
推荐引用方式
GB/T 7714：

Yang Yun-Song,Chen Ying-Le,Di Gen-Hong, et al. Prognostic value of primary tumor surgery in de novo stage IV breast cancer patients with different metastatic burdens: a propensity score-matched and population-based study [J].TRANSLATIONAL CANCER RESEARCH,2019,8(2):614-+.
APA：

Yang Yun-Song,Chen Ying-Le,Di Gen-Hong,Jiang Yi-Zhou,&Shao Zhi-Ming.(2019).Prognostic value of primary tumor surgery in de novo stage IV breast cancer patients with different metastatic burdens: a propensity score-matched and population-based study .TRANSLATIONAL CANCER RESEARCH,8(2):614-+.
MLA：

Yang Yun-Song, et al. "Prognostic value of primary tumor surgery in de novo stage IV breast cancer patients with different metastatic burdens: a propensity score-matched and population-based study" .TRANSLATIONAL CANCER RESEARCH 8,2(2019):614-+.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：7  下载次数：0

分享到：

浏览次数：7

下载次数：0

打印次数：0